Tempus AI, Inc. (TEM) shares tumbled 13.8% to $71.98 as of October 6, 2026, a sharp decline from the prior close of $83.55. BestStocks flagged the session as a major change for TEM. The move is tied to price move down. Below, we break down what changed for TEM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
TEM fell 13.8% to $71.98
Tempus AI, Inc. (TEM) moved -15.28% from $84.97 to $71.98 on 2026-10-06 on volume 2.6x the 5-day average. We checked news, earnings, analyst updates, filings, and corporate actions. The only company-specific event found was an announcement that Tempus AI launched FDA-cleared AI-ECG tools to expand its cardiovascular diagnostic portfolio—a product expansion, not an earnings miss or negative catalyst. Earnings scheduled for 2026-11-03 will be the next catalyst; consensus EPS estimate is -$0.07.
This summary describes the catalyst and move as first detected on Oct 6, 2026, 4:38 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsMedium confidence
Rel. volume
2.4×
Very High
Vs peers
—
No comparable peers
Market cap
$12.6B
NASDAQ
Analyst target
$73
+0.9% vs price
Price chart
Sep 8 – Oct 6
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Tempus AI, Inc. investors
For Tempus AI, Inc. investors, the recent signals add up to a strong bearish shift. Weighing against that: Material negative event; Sharp 13.8% decline — elevated risk. Wall Street's consensus price target sits at $72.60, implying +0.9% upside from $71.98. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality medium (70/100). With earnings roughly 28 days out, the next report is the most likely near-term test of the move.
TEM price reaction
TEM last traded at $71.98, down $11.57 (-13.85%) from the previous close of $83.55. The session traded on 2.4× average volume (very high), so the move carried above-average conviction. Over the past month the stock has ranged between $58.74 and $85.08, and it currently sits about 50% of the way up that band.
Bullish and bearish analyst opinions on Tempus AI, Inc. (TEM)
▼Latest catalyst·a bearish counterpoint
The latest catalyst — a materially negative development — a bearish counterpoint that challenges the prevailing bullish analyst view.
The consensus analyst price target on Tempus AI, Inc. (TEM) is $72.60, 0.9% above the recent $71.98. Over the past 90 days analysts logged 1 upgrade, 11 maintains, and 0 downgrades. Here is how the bullish and bearish cases on TEM line up.
▲ The bullish case
+Wall Street's consensus price target of $72.60 implies +0.9% upside from $71.98.
+The Street's most bullish target is $92.00 (+27.8%).
+1 analyst upgrade in the past 90 days, most recently Piper Sandler to Overweight (2026-09-01).
▼ The bearish case
−The most bearish analyst target is $50.00 (-30.5%).
−Material negative event.
−Sharp 13.8% decline — elevated risk.
−High volume 2.4x on decline — distribution signal.
−Tempus AI fell 6.11% to $76.90 despite announcing 13 abstracts accepted for presentation at the European Society for Medical Oncology Congress 2026 (Business Wire).
Bull vs bear balanceStrong Bearish Shift
BearishNeutralBullish
The latest catalyst moved the balance toward the bears — the hollow tick marks where it sat before.
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 6, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Tempus AI rose 6.47% to $81.59, driven by positive market focus on its expanding cardiovascular portfolio and recent FDA clearances for diagnostic AI products, particularly its ECG-PH offering. The web catalyst cited regulatory momentum and strategic positioning within the AI-ECG market, forecasted to reach $2.40 billion in 2026 with 19.3% CAGR. Volume of 2.82M shares was 1.13x the session-adjusted average, reflecting normal trading activity.
Tempus AI fell 6.11% to $76.90 despite announcing 13 abstracts accepted for presentation at the European Society for Medical Oncology Congress 2026 (Business Wire). The decline occurred on volume 0.98x the expected daily average, suggesting the positive research milestone did not offset broader selling pressure or profit-taking in the session.
News2026-10-01-6.6%
Tempus secured 13 abstract presentations at ESMO Congress 2026, showcasing clinical research in oncology.
News2026-09-28+0.1%
Tempus AI received FDA 510(k) clearance for ECG-MR, an AI product detecting undiagnosed mitral regurgitation from standard ECGs.
Tempus AI, Inc. moved +3.61% intraday from $82.24 to $85.21. Tempus AI, Inc. (TEM) shares are trading higher, building on a massive multi-week rally driven by a string of major announcements in precision medicine, data licensing, and AI-driven diagnostics . The stock recently surged roughly 40% and reached around $82.68 per share in recent trading sessions.The primary catalysts fueling investor optimism include: ### 1. Extended Data Licensing Deal with Recursion Pharmaceuticals Tempus AI recently announced an extension of its existing data licensing partnership with Recursion Pharmaceuticals through 2029. The restructured agreement guarantees $42 million in committed payments (replacing a previous structure of up to $84 million in discretionary milestones). Crucially, the agreement grants Tempus a license to use Recursion’s RNA foundation model , substantially bolstering its bioinformatics capabilities. ### 2. Launch of the Multimodal Whole-Genome Dataset Investor sentiment has been strongly boosted by Tempus launching an aggressive initiative to build the world's largest multimodal whole-genome dataset . The company aims to sequence 100,000 whole genomes initially, with long-term plans to scale up to 1 million genomes to accelerate AI-drive
Tempus AI, Inc. moved +5.26% intraday from $76.59 to $80.62. ### 💡 Why Tempus AI (TEM ) Moved on September 24, 2026 - Market Context: Broad sector enthusiasm for AI—sparked by developments like Meta 's Muse AI assistant rollout—has created positive momentum across artificial intelligence equities. - Recent Catalysts: Tempus AI recently presented at the Morgan Stanley Global Healthcare Conference and gained traction following a $62.7M ARPA-H funding announcement for AI-driven heart failure care. - Session Action: Despite minor intraday fluctuations and ongoing investor scrutiny regarding profitability, TEM held steady with modest positive movement in line with general tech-sector tailwinds.
Material / Earnings2026-09-17+14.8%
Tempus AI, Inc. (TEM) moved +10.38% to $80.36 on September 17, 2026, after Piper Sandler upgraded the stock to Overweight from Neutral and raised its price target to $76 from $56. The company also secured up to $9.5 million in federal funding through ARPA-H ADVOCATE for autonomous AI cardiology development, and continued market optimism around its pending Personalis acquisition added to the upward momentum.
Tempus AI surged +10.26% to $68.59 following CEO Eric Lefkofsky's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference today, where management highlighted surging demand in diagnostics and accelerating expansion of its high-margin data licensing business (Seeking Alpha). The gain also reflects positive sentiment from the company's announced initiative to build a 100,000 whole-genome research database paired with clinical outcomes. Volume of 5.9M shares is tracking 0.84x expected levels for this point in the session.
In-depth TEM event analyses
Permanent, dated analyses of TEM's most significant sessions.
TEM tumbled 13.8% to $71.98. The move is associated with price move down.
How much did TEM stock fall?
TEM lost 13.85% ($11.57) versus the prior close of $83.55, last trading at $71.98 on 2.4× average volume.
When is Tempus AI, Inc.'s next earnings date?
TEM's next earnings report is estimated for 2026-11-03 — about 28 days away.
What is the analyst price target for TEM?
The consensus analyst price target for TEM is $72.60, about 0.9% above the current $71.98. Over the past 90 days, analysts recorded 1 upgrade, 11 maintains, and 0 downgrades.
How BestStocks tracks TEM
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for TEM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 6, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
